Infertility Evaluation: ASRM/AUA Workup, Semen Analysis, and Treatment Cascade
A practical, evidence-based framework for the basic infertility evaluation — when to start the workup, how to interpret semen analysis under WHO 2021 reference values, ovarian reserve testing, tubal assessment, and the stepwise progression from ovulation induction through IUI to assisted reproduction.
Executive Summary
Infertility — failure to conceive after 12 months of unprotected, well-timed intercourse (or 6 months if the female partner is ≥35 years) — affects approximately one in seven heterosexual couples and warrants a coordinated bilateral evaluation rather than a stepwise gendered referral. The basic workup, completed in two to three menstrual cycles, must include semen analysis (the single highest-yield first test, abnormal in 30–40% of cases), confirmation of ovulation, ovarian reserve assessment with antimüllerian hormone (AMH) and antral follicle count (AFC), and tubal patency by hysterosalpingography (HSG). Causes distribute as male factor 30–40%, ovulatory dysfunction 25–30%, tubal/peritoneal disease 25–35%, and unexplained infertility 10–15%, with significant overlap. Treatment escalates rationally: lifestyle modification, ovulation induction with letrozole 2.5–7.5 mg or clomiphene citrate 50–150 mg on cycle days 3–7, intrauterine insemination, and finally in vitro fertilization with or without intracytoplasmic sperm injection. Age is the dominant prognostic variable: live-birth rate per IVF cycle drops from ~40% under 35 to ~7% over 42, and any evaluation must place the female partner’s age at the center of counseling.
1 · Definitions, Epidemiology & When to Refer
The American Society for Reproductive Medicine (ASRM) and American Urological Association (AUA) jointly define infertility as the failure to achieve a clinical pregnancy after twelve months or more of regular, unprotected intercourse. The threshold collapses to six months when the female partner is ≥35 years, and immediate evaluation is warranted when she is ≥40, when there is known anovulation (e.g., PCOS, hypothalamic amenorrhea), prior pelvic surgery, endometriosis, exposure to gonadotoxic chemotherapy/radiation, or a male partner with known andrological disease. The evaluation framework deliberately treats the couple as the unit of care: roughly one-third of cases trace to male factor, one-third to female factor, and one-third to combined or unexplained etiology, so a unilateral workup is both inefficient and inequitable.
When to begin the evaluation
| Female age | Trigger for evaluation | Notes |
|---|---|---|
| < 35 years | ≥ 12 months of failed conception | Standard baseline; counsel on cycle tracking first |
| 35–39 years | ≥ 6 months of failed conception | Initiate workup in parallel with continued attempts |
| ≥ 40 years | Immediate (do not wait) | Counsel on AMH-driven IVF window; oocyte cryo if delaying |
| Any age + red flag | Immediate | Anovulation, prior chemo/radiation, endometriosis, PID, surgery, partner azoospermia |
Etiology distribution (overlapping categories)
- Male factor: 30–40% — semen abnormalities, varicocele, ejaculatory dysfunction, obstructive/non-obstructive azoospermia.
- Ovulatory dysfunction: 25–30% — polycystic ovary syndrome (most common), hypothalamic amenorrhea, hyperprolactinemia, thyroid disease, premature ovarian insufficiency.
- Tubal/peritoneal: 25–35% — chlamydia/gonorrhea sequelae, endometriosis, prior pelvic surgery, hydrosalpinx.
- Uterine: 5–10% — submucous fibroid, polyp, intrauterine adhesions (Asherman), congenital müllerian anomaly.
- Unexplained: 10–15% — full standard workup negative.
2 · Female Workup: Ovulation, Ovarian Reserve, Anatomy
The female evaluation answers three questions in sequence: Is she ovulating? How much oocyte reserve is left? Are the tubes and uterine cavity normal? Each pillar carries a preferred test and a fallback, and the panel is generally completed within two menstrual cycles before therapeutic decisions are made.
Pillar 1 — Ovulation confirmation
- History first. Cycles 24–35 days with reliable molimina (mittelschmerz, premenstrual breast tenderness) are 95% predictive of ovulation; oligomenorrhea (>35 d) or amenorrhea is presumptive anovulation.
- Mid-luteal serum progesterone drawn ~7 days before expected menses (cycle day 21 in a 28-day cycle): ≥ 3 ng/mL confirms ovulation; ≥ 10 ng/mL suggests adequate luteal phase.
- Urinary LH kits identify the LH surge ~24–36 hours before ovulation; useful for cycle timing but a positive surge alone is not proof of ovulation.
- Anovulation workup: TSH, prolactin, FSH/LH/estradiol on cycle day 3, total testosterone and DHEA-S if hyperandrogenism, 17-OH progesterone if congenital adrenal hyperplasia suspected.
Pillar 2 — Ovarian reserve testing
Ovarian reserve does not predict natural fecundability in young women, but it is indispensable for IVF dose planning, counseling about reproductive lifespan, and identifying premature ovarian insufficiency. The contemporary panel relies on AMH and AFC; day-3 FSH is now an adjunct.
| Test | Method | Reassuring | Diminished reserve |
|---|---|---|---|
| AMH | Serum, any cycle day | 1.0–4.0 ng/mL | < 1.0 ng/mL (very low < 0.5) |
| AFC | Transvaginal US, early follicular | 10–20 follicles (both ovaries) | < 5–7 follicles total |
| Day-3 FSH | Serum on cycle day 2–4 | < 10 mIU/mL | > 10 mIU/mL (severely > 20) |
| Day-3 estradiol | Paired with FSH | < 80 pg/mL | > 80 pg/mL (may falsely suppress FSH) |
Pillar 3 — Tubal & uterine assessment
- Hysterosalpingography (HSG) — first-line. Performed cycle days 5–10 (post-menstrual, pre-ovulatory). Sensitivity for tubal occlusion ~65%, specificity ~85%; oil-soluble contrast may also confer a modest fertility-enhancing effect (H2Oil trial).
- Saline infusion sonohysterography (SIS) for cavity assessment when HSG suggests filling defect or polyp/fibroid suspected.
- Hysteroscopy when SIS or HSG abnormal — gold standard for cavity, allows simultaneous resection.
- Diagnostic laparoscopy reserved for suspected endometriosis or distal tubal disease; not first-line because morbidity exceeds yield in the absence of pelvic pain or prior PID.
3 · Male Workup: WHO 2021 Semen Analysis
Semen analysis is the cornerstone male test and should be obtained early — ideally before any female testing escalates beyond cycle-day labs. The WHO 6th edition (2021) lower reference limits replace the previous WHO 2010 thresholds and represent the lowest 5th centile of fertile men whose partner conceived within 12 months. Two abnormal samples spaced 1–3 months apart are required to confirm an abnormality, since intra-individual variability is substantial.
| Parameter | WHO 2021 lower reference (5th centile) | Term for abnormality |
|---|---|---|
| Semen volume | ≥ 1.4 mL | Hypospermia |
| Sperm concentration | ≥ 16 million/mL | Oligozoospermia |
| Total sperm number | ≥ 39 million/ejaculate | Oligozoospermia (total) |
| Total motility (PR + NP) | ≥ 42% | Asthenozoospermia |
| Progressive motility | ≥ 30% | Asthenozoospermia (PR) |
| Normal morphology (strict) | ≥ 4% | Teratozoospermia |
| Vitality (live) | ≥ 54% | Necrozoospermia |
| Azoospermia | No sperm in centrifuged pellet | Endocrine + genetic workup |
Specimen collection rules
- Abstinence 2–7 days (deviating either way changes concentration).
- Collected by masturbation into a sterile, non-spermicidal container; whole ejaculate must be captured.
- Delivered to lab within 60 minutes, kept at body temperature.
- If clinic collection impossible, special non-toxic collection condoms exist (no latex).
Workup of abnormal semen
For severe oligospermia (< 5 million/mL) or azoospermia, escalate immediately:
- Hormonal panel — total testosterone (8–10 a.m.), FSH, LH, prolactin, estradiol, TSH. Elevated FSH with low testosterone → primary testicular failure; low/normal FSH with low testosterone → secondary (hypogonadotropic).
- Genetic testing in azoospermia or severe oligospermia — karyotype (Klinefelter 47,XXY found in 5–10%), Y-chromosome microdeletion (AZFa/b/c), CFTR mutation (congenital absence of vas deferens).
- Scrotal ultrasound for varicocele, mass, ductal abnormality.
- Post-ejaculate urinalysis if low volume / azoospermia — sperm in urine indicates retrograde ejaculation.
- Urology referral for varicocelectomy candidacy, microsurgical TESE in non-obstructive azoospermia, or vasal reconstruction.
4 · Treatment Cascade: OI → IUI → IVF
The treatment ladder is anchored on female age, ovarian reserve, and the specific diagnosis. For ovulatory dysfunction with patent tubes and a normal semen analysis, ovulation induction is first-line; for unexplained infertility, the AMIGOS/FORTT/FASTT trials support up to three IUI cycles before escalation; for tubal disease, severe male factor, or age ≥40 with low reserve, direct-to-IVF saves time and money.
Ovulation induction — letrozole vs clomiphene
| Drug | Mechanism | Dose | Notes |
|---|---|---|---|
| Letrozole (preferred for PCOS) | Aromatase inhibitor → ↓ estrogen → ↑ FSH | 2.5 mg PO daily × 5 d, cycle days 3–7; titrate to 5–7.5 mg | Higher live-birth than clomiphene in PCOS (PPCOS-II); off-label but ASRM/ACOG endorsed |
| Clomiphene citrate | Selective estrogen receptor modulator (hypothalamus) | 50 mg PO daily × 5 d, cycle days 3–7 (or 5–9); up to 150 mg | Anti-estrogenic effects on cervical mucus and endometrium; 6-cycle maximum |
| Metformin (PCOS adjunct) | Insulin sensitizer | 500 mg PO TID titrate to 1500–2000 mg/day | Use if BMI > 30 or insulin resistance; not standalone fertility drug |
Cycle monitoring includes mid-cycle transvaginal ultrasound to confirm a dominant follicle (~18–24 mm) and an LH surge or hCG trigger. Progesterone is checked 7 days after ovulation. Move to next step after 3–6 ovulatory cycles without conception.
Gonadotropins & intrauterine insemination
IUI bypasses the cervix by depositing washed, motile sperm directly into the uterine cavity timed to ovulation, raising per-cycle pregnancy rates to ~10–15%. It is most effective when paired with ovulation induction (clomiphene/letrozole or low-dose injectable FSH such as menotropins 75 IU SC daily with serial follicular monitoring). Three IUI cycles are typically attempted before IVF. Risks include multiple gestation (~10%) and ovarian hyperstimulation syndrome with gonadotropins.
- Indications: mild-moderate male factor (post-wash motile count ≥ 5–10 million), unexplained infertility, cervical factor, sexual dysfunction, single individuals or same-sex female couples using donor sperm.
- Contraindications: bilateral tubal occlusion, severe male factor (post-wash < 5 million), advanced maternal age with low reserve.
- Trigger: recombinant hCG 250 mcg SC or urinary hCG 5,000–10,000 IU SC when lead follicle ≥ 18 mm; insemination 24–36 h later.
In vitro fertilization, ICSI, and PGT
IVF involves controlled ovarian hyperstimulation (typically antagonist protocol with recombinant FSH 150–300 IU SC daily ± low-dose hMG, GnRH antagonist cetrorelix 0.25 mg SC daily from day 5–6, GnRH agonist trigger or hCG trigger), transvaginal oocyte retrieval 34–36 hours later, fertilization in the lab, and embryo transfer (fresh or frozen). Per-cycle live-birth rates depend overwhelmingly on female age:
| Female age | IVF live-birth/cycle (US SART data) | Multiple gestation (single ET) |
|---|---|---|
| < 35 | ~40–45% | ~1.5% |
| 35–37 | ~30–35% | ~1.5% |
| 38–40 | ~20–25% | ~1% |
| 41–42 | ~10–15% | < 1% |
| > 42 | ~5–7% | < 1% |
| Donor egg (any age) | ~50% | ~1.5% |
ICSI indications
- Severe male factor (low concentration, motility, or morphology)
- Surgically retrieved sperm (TESA, TESE, MESA)
- Prior IVF cycle with low/zero fertilization
- Need for PGT (single sperm injection prevents extraneous DNA contamination)
Preimplantation genetic testing
- PGT-A — aneuploidy screening; useful in advanced maternal age, recurrent pregnancy loss, recurrent IVF failure (STAR trial showed mixed benefit; not routine).
- PGT-M — single-gene disorders (CF, sickle cell, Tay-Sachs, BRCA carriers electing prevention).
- PGT-SR — structural rearrangements (balanced translocation carriers).
5 · Special Populations & Counseling
Standard pathways require modification for several patient groups; the table below distills the most common adjustments.
| Population | Workup adjustment | Treatment adjustment |
|---|---|---|
| PCOS | Add OGTT, fasting lipid, 17-OH progesterone if hyperandrogenism | Letrozole first-line; metformin if BMI > 30; weight loss 5–10% restores ovulation in ~40% |
| Hypothalamic amenorrhea | Low FSH/LH/E2; check eating disorder, exercise stress | Restore caloric intake / reduce exercise; pulsatile GnRH or gonadotropins for OI; clomiphene/letrozole ineffective (no functional axis) |
| Diminished ovarian reserve | AMH < 1.0, AFC < 7, FSH > 10 | Skip OI/IUI ladder; proceed directly to IVF; counsel donor egg early; DHEA 25 mg PO TID × 12 wk pre-IVF (controversial) |
| Endometriosis | CA-125 elevated > 35 in 50%; pelvic US for endometrioma; laparoscopy for definitive Dx | Stage I/II — surgical ablation modestly improves; Stage III/IV — proceed to IVF; cyst > 4 cm consider cystectomy first |
| Hydrosalpinx | HSG or US shows dilated tube | Laparoscopic salpingectomy or proximal occlusion before IVF (doubles live-birth rate) |
| Recurrent pregnancy loss (≥ 2) | Karyotype both partners, antiphospholipid Ab, TSH, prolactin, hysteroscopy | Treat underlying cause; PGT-A if structural rearrangement; aspirin + LMWH for confirmed APS |
| Oncofertility (pre-chemo) | Urgent same-day REI; AMH baseline | Random-start ovarian stim with letrozole co-administration (BRCA/breast Ca); oocyte or embryo cryopreservation; ovarian tissue cryo if < 2 wk |
| Same-sex female couples / single women | Standard female workup; donor sperm screening | IUI with donor sperm; reciprocal IVF (one partner provides oocyte, other carries) on request |
| Klinefelter (47,XXY) | Karyotype confirms; check FSH, T, semen analysis (usually azoospermia) | Microsurgical TESE — sperm retrieval ~50%; ICSI; testosterone replacement only after fertility plan finalized |
Pre-conception counseling — checklist
- Folic acid 400–800 mcg PO daily (4 mg if prior NTD, on antiepileptic, or diabetic).
- Smoking cessation, alcohol < 1 drink/day, recreational drug discontinuation.
- BMI optimization 19–30 (every 5-unit increase above 25 reduces fecundability ~5%).
- Vaccinations updated: MMR, varicella, Tdap, influenza, COVID-19.
- Screen for diabetes, thyroid disease, hypertension, anemia, hepatitis B/C, HIV.
- Genetic carrier screening (CF, SMA, hemoglobinopathies, ethnicity-specific panel).
- Optimize chronic medications (avoid teratogens — ACE-I, statins, isotretinoin, valproate; switch SSRI to safer agent if needed).
6 · Pearls, Pitfalls & FAQ
✓ Pearl 1 — Couple, not the woman
Always order semen analysis before HSG. Male factor accounts for 30–40% of cases, the test costs less than HSG, carries no procedural risk, and can spare an unnecessary tubal study. The reverse order is one of the most common workup errors in primary care.
✗ Pitfall 1 — “Just keep trying”
Watchful waiting beyond the formal ASRM/AUA threshold is harmful, not benign — for a 38-year-old woman, every six months of delayed evaluation costs roughly 5% absolute live-birth chance per IVF cycle. Initiate workup at six months if she is ≥35; immediately if ≥40 or red flags present.
✓ Pearl 2 — Letrozole over clomiphene in PCOS
The PPCOS-II trial showed letrozole produced 27.5% live-birth vs 19.1% with clomiphene in PCOS women (NEJM 2014). Letrozole avoids clomiphene’s anti-estrogenic endometrial thinning and cervical mucus effects. It remains off-label for ovulation induction but is endorsed by ASRM as first-line for PCOS.
✗ Pitfall 2 — Repeating semen with no abstinence control
Specimens collected with < 2 days or > 7 days of abstinence have artificially low concentration or volume. A semen analysis with uncontrolled abstinence or single-sample abnormality should not drive a referral; obtain two specimens 1–3 months apart with documented 2–7 day abstinence before labeling male factor.
✓ Pearl 3 — Treat hydrosalpinx before IVF
A dilated, fluid-filled tube reduces IVF live-birth by ~50% via reflux of cytotoxic fluid into the uterine cavity. Laparoscopic salpingectomy (preferred) or proximal tubal occlusion before embryo transfer roughly doubles live-birth rate (Cochrane 2010). Counsel and refer aggressively.
✗ Pitfall 3 — Treating “low AMH” in young women with watchful waiting
AMH does not predict natural fecundability in women < 35 — it predicts ovarian response to IVF stimulation. A young woman with low AMH and otherwise normal workup can still conceive naturally; however, urgency for evaluation increases because reproductive runway is shorter than chronologic age suggests.
Frequently asked questions
Practice Insights: Lessons from a Decade in a Mixed PCP–Reproductive-Endocrine Practice
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Whether to work a couple up now or wait another six months is the decision that shapes infertility care, because the workup is mostly about not wasting the patient’s ovarian reserve clock and not misinterpreting biomarkers in either direction. In experienced practice the patterns experienced clinicians track most carefully are the chronic referral delay in women over 35, the AMH overinterpretation that distorts couples’ expectations, the WHO 2021 semen-analysis cutoff confusion in primary care, and the temptation to layer three to six cycles of empiric ovulation induction on women who actually ovulate normally.
1. Refer at Six Months for Women 35–39, Immediately for ≥ 40
The pattern experienced clinicians see most often in primary care is a 38-year-old patient politely advised to “try for another six months” and then “another six months” before any workup is ordered. In experienced practice that conversation costs the couple roughly 15% of remaining oocyte reserve per year, and the resulting IVF cycle outcome is materially worse than it would have been twelve months earlier. Seasoned clinicians now refer any woman between 35 and 39 after exactly six months of unprotected intercourse without conception, and any woman 40 or older at presentation regardless of trying duration. The patient may decline the workup — that is their decision, not the clinician’s — but the conversation needs to happen.
2. AMH Is Not a “Fertility Test”
One of the most damaging miscommunications experienced practitioners encounter is the patient who arrives clutching a direct-to-consumer AMH result and tells them they are “still very fertile” or “running out of time” based on that number alone. In practice they now reframe AMH explicitly: it predicts how many eggs will likely be recovered during ovarian stimulation, and it loosely correlates with the timing of menopause at a population level. It does not predict whether they will conceive this cycle, this year, or whether they can safely defer pregnancy. Experienced clinicians would rather have an uncomfortable five-minute reframe than have the patient make childbearing decisions on a misread biomarker.
3. WHO 2021 Reclassified a Lot of “Abnormal” Semen as Normal
The semen analyses seasoned clinicians see referred to them are still being interpreted against WHO 2010 thresholds half the time, and clinicians have learned to always recheck against WHO 2021 before believing a “male factor” label. The biggest shifts in practice are progressive motility dropping from 32% to 30% and total motility rising from 40% to 42%, with the morphology cutoff at 4% essentially unchanged but increasingly de-emphasized clinically. Any genuinely abnormal result requires a second sample at least three weeks later with a documented three-day abstinence period — single-sample diagnoses are not actionable in experienced hands.
4. Empiric OI Is for Anovulators, Not Everyone
The single most common time-wasting mistake experienced practitioners see in community-based fertility care is empiric letrozole or clomiphene given to women who are ovulating normally. The evidence is consistent: in normo-ovulatory unexplained infertility, three to six cycles of oral ovulation induction produce minimal improvement in live-birth rate compared with the same time spent on expectant management or moving to IVF. In experienced practice clinicians reserve letrozole for true anovulation (PCOS, oligomenorrhea with absent LH surge on monitoring), and experienced clinicians move normo-ovulatory unexplained infertility directly to a structured IUI-plus-stimulation cascade with a firm three-cycle ceiling before IVF.
Illustrative Scenario
A patient in her late thirties presented to primary care after 14 months of unprotected intercourse without conception. She had regular menses with documented mid-luteal progesterone of 12 ng/mL on a prior cycle, no risk factors for tubal disease, and a partner with a normal-appearing semen analysis interpreted under the older 2010 thresholds. A consumer-tested AMH was returned at 1.1 ng/mL, and she had been told by another clinician that this meant she was “in perimenopause” and “should consider donor eggs.”
The treating clinicians reframed the AMH explicitly as a stimulation-response marker rather than a fertility verdict. Workup proceeded with day-3 FSH/estradiol (FSH 9.8, estradiol 48), antral follicle count of 7 (low-normal for age), thyroid and prolactin normal, hysterosalpingogram with patent tubes. Repeat semen analysis interpreted under WHO 2021 was normal in all parameters with a borderline morphology of 3% that no longer carries the prognostic weight it once did. The couple was counseled as normo-ovulatory unexplained infertility with low-normal ovarian reserve; rather than three to six cycles of empiric letrozole, the treating clinicians moved directly to three cycles of IUI with letrozole stimulation, and to IVF if needed. Pregnancy occurred on the second IUI cycle.
Takeaway: A low AMH in a normo-ovulatory patient is not a verdict; it is a stimulation-yield prediction. Reframe before the patient builds a life decision on it.
Standing Protocol Adjustments
- Initiate workup at six months for women 35–39, and immediately for women 40 and older, regardless of patient preference for more “natural” trying time; document the conversation and let the patient decline the workup if they choose.
- Reframe AMH at every encounter as a marker of stimulation response and rough menopause-timing at the population level, not as a fertility verdict; never deliver an AMH number without context.
- Interpret every semen analysis against WHO 2021 thresholds and require a second confirmatory sample ≥ 3 weeks apart with documented 2–7 day abstinence; never act on a single abnormal result.
- Reserve letrozole and clomiphene for true anovulation; move normo-ovulatory unexplained infertility directly to a structured three-cycle IUI plus stimulation cascade, then to IVF, rather than layering empiric oral OI.
- Pap Smear Interpretation: Bethesda 2014 and ASCCP 2019
- HPV Vaccination in the OB/GYN Clinic: Schedule, Efficacy, and Catch-Up Strategy
- Twin-to-Twin Transfusion Syndrome: Quintero Staging, Fetoscopic Laser, and Surveillance
- Asherman Syndrome: Hysteroscopic Adhesiolysis and Fertility Restoration
- Heavy Menstrual Bleeding: PALM-COEIN Workup, Medical First-Line, and Surgical Escalation
- Premature Ovarian Insufficiency: FSH Diagnosis, Hormone Replacement